Prakt. Lékáren. 2016; 12(6e) [Interní Med. 2016; 18(2): 78-82]

New peroral antidiabetic drugs and heart failure

Jana Jiráčková^{1, 2}, Alena Šmahelová^{1, 3}

¹ III. interní gerontometabolická klinika, Fakultní nemocnice Hradec Králové

² Ústav klinické biochemie a diagnostiky, Fakultní nemocnice Hradec Králové

³ Univerzita Karlova v Praze, Lékařská fakulta Hradec Králové

Important risk factors of chronic heart failure (CHF) i diabetics represent ischaemic heart disease and arterial hypertension as well as diabetic cardiomyopathy(specific heart tissue impairment of diabetes mellitus). Optimal diabetic compensation is essential for prevention and treatment ofCHF. A wide range of antidiabetic drugs can lower effectively blood glucose as well as improve cardiovascular parameters. Metformin – traditional antidiabetic drug is a very effective insulin sensitizer with positive cardiovascular effect; metformin can be used in patients with compensatedCHF. Gliptins, modern peroral antidiabetic drugs, are used in patients with cardiovascular complications however results of recent cardiovascularstudies (SAVOR, TECOS, EXAMINE) were a bit confusing. Gliflozines on the other hand have become very promising for patients with CHF, basedon results of EMPA-REG presenting statistically significant reduction in cardiovascular mortality and complications of chronic heart failure.

Keywords: chronical heart failure, gliflozins, gliptins

Published: December 1, 2016  Show citation